'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patients

Oncology Letters

Volumn 7, Issue 6, 2014, Pages 1761-1766

  Fang, Weijia ^a   Radovich, Milan ^b   Zheng, Yulong ^a   Fu, Cai Yun ^c   Zhao, Peng ^a   Mao, Chengyu ^a   Zheng, Yi ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

Druggable alterations; Formalin fixed paraffin embedded; Ion Torrrent; Metastasic colorectal cancer

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PROTEIN 53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL ARTICLE; COMPUTER PROGRAM; DNA EXTRACTION; EXON; FEMALE; GENE LOCUS; GENE SEQUENCE; HUMAN; HUMAN TISSUE; ION TORRENT; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; WNT SIGNALING; YOUNG ADULT;

EID: 84898875816     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2047     Document Type: Article

References (23)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63: 11-30, 2013.
2. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ and Stratton MR: Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3: 246-259, 2013.
3. Bamford S, Dawson E, Forbes S, et al: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 91: 355-358, 2004.
4. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39: D945-D950, 2011.
5. Alexandrov LB, Nik-Zainal S, Wedge DC, et al; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain: Signatures of mutational processes in human cancer. Nature. 500: 415-421, 2013.
6. O'Hanlon LH: How next-generation sequencing could change cancer care. J Natl Cancer Inst. 105: 836-838, 2013.
7. Rothberg JM, Hinz W, Rearick TM, et al: An integrated semiconductor device enabling non-optical genome sequencing. Nature. 475: 348-352, 2011.
8. Nishino M, Jackman DM, Hatabu H, et al: New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 195: W221-W228, 2010.
9. Schewe C, Goldmann T, Grosser M, et al: Inter-laboratory validation of PCR-based detection of Mycobacterium tuberculosis in formalin-fixed, paraffin-embedded tissues. Virchows Arch. 447: 573-585, 2005.
10. Hadd AG, Houghton J, Choudhary A, et al: Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn. 15: 234-247, 2013.
11. Quail MA, Smith M, Coupland P, et al: A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics. 13: 341, 2012.
12. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C and Van Cutsem E: Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 30: 3570-3577, 2012.
13. Wu S, Gao Y, Dong X, et al: Serum metabonomics coupled with Ingenuity Pathway Analysis characterizes metabolic perturbations in response to hypothyroidism induced by propylthiouracil in rats. J Pharm Biomed Anal. 72: 109-114, 2013.
14. Cho KH, Baek S and Sung MH: Wnt pathway mutations selected by optimal beta-catenin signaling for tumorigenesis. FEBS Lett. 580: 3665-3670, 2006.
15. Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7: 606-619, 2006.
16. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2: 489-501, 2002.
17. Yang G and Yang X: Smad4-mediated TGF-beta signaling in tumorigenesis. Int J Biol Sci. 6: 1-8, 2010.
18. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487: 330-337, 2012.
19. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364: 2507-2516, 2011.
20. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66: 3992-3995, 2006.
21. Okamoto K, Neureiter D, Alinger B, et al: The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int J Oncol. 33: 733-742, 2008.
22. Traxler P, Allegrini PR, Brandt R, et al: AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64: 4931-4941, 2004.
23. Serra V, Markman B, Scaltriti M, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68: 8022-8030, 2008.